Compassionate Use of Dupilumab

Studies

Study First Submitted Date 2021-02-25
Study First Posted Date 2021-03-02
Last Update Posted Date 2022-07-29
Verification Month Year July 2022
Verification Date 2022-07-31
Last Update Posted Date 2022-07-29

Detailed Descriptions

Sequence: 20793939
Description Compassionate Use requests are only being considered in response to Individual Patient Investigational New Drug (IND) applications. Availability will depend on location.

Conditions

Sequence: 52357109 Sequence: 52357110 Sequence: 52357111 Sequence: 52357112
Name Bullous Pemphigoid Name Pediatric Eosinophilic Esophagitis (EoE) Name Pediatric Asthma Name Pediatric and Adolescent Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Downcase Name bullous pemphigoid Downcase Name pediatric eosinophilic esophagitis (eoe) Downcase Name pediatric asthma Downcase Name pediatric and adolescent chronic rhinosinusitis with nasal polyps (crswnp)

Id Information

Sequence: 40291737
Id Source org_study_id
Id Value R668-Dupilumab

Interventions

Sequence: 52668048
Intervention Type Drug
Name Dupilumab

Browse Conditions

Sequence: 194193863 Sequence: 194193864 Sequence: 194193865 Sequence: 194193866 Sequence: 194193867 Sequence: 194193868 Sequence: 194193869 Sequence: 194193870 Sequence: 194193871 Sequence: 194193872 Sequence: 194193873 Sequence: 194193874 Sequence: 194193875 Sequence: 194193876 Sequence: 194193877 Sequence: 194193878 Sequence: 194193879 Sequence: 194193880 Sequence: 194193881 Sequence: 194193882 Sequence: 194193883 Sequence: 194193884
Mesh Term Esophagitis Mesh Term Eosinophilic Esophagitis Mesh Term Nasal Polyps Mesh Term Pemphigoid, Bullous Mesh Term Esophageal Diseases Mesh Term Gastrointestinal Diseases Mesh Term Digestive System Diseases Mesh Term Gastroenteritis Mesh Term Eosinophilia Mesh Term Leukocyte Disorders Mesh Term Hematologic Diseases Mesh Term Hypersensitivity, Immediate Mesh Term Hypersensitivity Mesh Term Immune System Diseases Mesh Term Nose Diseases Mesh Term Respiratory Tract Diseases Mesh Term Otorhinolaryngologic Diseases Mesh Term Polyps Mesh Term Pathological Conditions, Anatomical Mesh Term Skin Diseases, Vesiculobullous Mesh Term Skin Diseases Mesh Term Autoimmune Diseases
Downcase Mesh Term esophagitis Downcase Mesh Term eosinophilic esophagitis Downcase Mesh Term nasal polyps Downcase Mesh Term pemphigoid, bullous Downcase Mesh Term esophageal diseases Downcase Mesh Term gastrointestinal diseases Downcase Mesh Term digestive system diseases Downcase Mesh Term gastroenteritis Downcase Mesh Term eosinophilia Downcase Mesh Term leukocyte disorders Downcase Mesh Term hematologic diseases Downcase Mesh Term hypersensitivity, immediate Downcase Mesh Term hypersensitivity Downcase Mesh Term immune system diseases Downcase Mesh Term nose diseases Downcase Mesh Term respiratory tract diseases Downcase Mesh Term otorhinolaryngologic diseases Downcase Mesh Term polyps Downcase Mesh Term pathological conditions, anatomical Downcase Mesh Term skin diseases, vesiculobullous Downcase Mesh Term skin diseases Downcase Mesh Term autoimmune diseases
Mesh Type mesh-list Mesh Type mesh-list Mesh Type mesh-list Mesh Type mesh-list Mesh Type mesh-ancestor Mesh Type mesh-ancestor Mesh Type mesh-ancestor Mesh Type mesh-ancestor Mesh Type mesh-ancestor Mesh Type mesh-ancestor Mesh Type mesh-ancestor Mesh Type mesh-ancestor Mesh Type mesh-ancestor Mesh Type mesh-ancestor Mesh Type mesh-ancestor Mesh Type mesh-ancestor Mesh Type mesh-ancestor Mesh Type mesh-ancestor Mesh Type mesh-ancestor Mesh Type mesh-ancestor Mesh Type mesh-ancestor Mesh Type mesh-ancestor

Sponsors

Sequence: 48492079
Agency Class INDUSTRY
Lead Or Collaborator lead
Name Regeneron Pharmaceuticals

Central Contacts

Sequence: 12055944
Contact Type primary
Name Requests for compassionate use must be initiated by a treating physician. Physicians should contact
Phone 844-734-6643
Email CompassionateUse_Requests@regeneron.com
Role Contact

Eligibilities

Sequence: 30872478
Minimum Age N/A
Maximum Age N/A
Adult True
Child True
Older Adult True

Calculated Values

Sequence: 254038802
Registered In Calendar Year 2021
Were Results Reported False
Has Single Facility False

Intervention Other Names

Sequence: 26768094 Sequence: 26768095 Sequence: 26768096
Intervention Id 52668048 Intervention Id 52668048 Intervention Id 52668048
Name REGN668 Name DUPIXENT® Name SAR231893

Responsible Parties

Sequence: 28984799
Responsible Party Type Sponsor